560 mg
Trade Name
Ibrutinib BOS
Film-coated tablet
Request Type
New Registration
Drug Type
Generic(Multisource) Drug
Approval Date
SFDA Approved Use
Ravulizumab is indicated for:
The treatment of adult and pediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal hemoglobinuria (PNH).
The treatment of adults and pediatric patients with a body weight of 10 kg or above with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Ibrutinib as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
·Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least prior therapy.
·Ibrutinib as a single agent is indicated for the treatment of adult patients with Waldenström"s macroglobulinaemia (WM) who have received at least prior therapy, or in first line treatment for patients unsuitable for chemoimmunotherapy.
·Ibrutinib in combination with rituximab is indicated for the treatment of adult patients with WM.
The treatment of adult and pediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal hemoglobinuria (PNH).
The treatment of adults and pediatric patients with a body weight of 10 kg or above with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Ibrutinib as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
·Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least prior therapy.
·Ibrutinib as a single agent is indicated for the treatment of adult patients with Waldenström"s macroglobulinaemia (WM) who have received at least prior therapy, or in first line treatment for patients unsuitable for chemoimmunotherapy.
·Ibrutinib in combination with rituximab is indicated for the treatment of adult patients with WM.